Drug Coated Balloon Drug-Coated Balloon ... - summitMD.com

More documents

Recommendations

Info

Fact #3: A PTA <strong>Balloon</strong> is Not An Ideal Platform (A Stent May Be Needed!) Expansion mechanism leads to: • Expansion in path of least resistance • Significant shear stress and trauma • High dissection rate • Elastic recoil • Abrupt closure • PTA study (2002) • 74 patients • 43% major dissections • 32% residual stenosis >30% • ABSOLUTE: Stent vs. PTA (2006) • 104 patients, 1:1 randomization • 32% insufficient PTA result led to cross over to stent • RESILIENT: Stent vs. PTA (2008) • 206 patients 2:1 randomization 40% PTA cross over to stent due to flow limiting dissections and residual stenosis • Pacifier: DEB vs. PTA (2011) • 91 patients, 1:1 randomization • 21% and 35% bail out stenting due to flow limiting dissections and residual stenosis Acute failure reported in ~30 - 40% of PTA case requiring additional treatment Slide (modified) courtesy of Eitan Konstantino
Vascular Healing of BMS-PCB Combination Compared to Taxus Stent in Coronaries of FHS AS 21.5%* AS 29.6%* # AS 55.1% # PES 2 nd nd Gen PCB + BMS p=0.01 BMS * *p=ns #p
Page 1 and 2: Drug-Coated Balloon Technologies I:
Page 3 and 4: Mechanism of Drug Delivery and Rest
Page 5 and 6: PACCOCATH ISR- F/U 5 Years Follow U
Page 7 and 8: Impact of Drug Retention (PK) on Va
Page 9 and 10: Mechanism of Action of DCB: Impact
Page 11 and 12: Paclitaxel Formulation Types Impact
Page 13 and 14: Second Generations Coatings Paclita
Page 15: Fact #2: PCB May Have Limited Effic
Page 19 and 20: Fact #4: Sirolimus Analogues • Ra
Page 21 and 22: Drug Eluting Balloon Nanoparticle B
Page 23 and 24: Opportunities for Improvement SIROL

Drug Coated Balloon Drug-Coated Balloon ... - summitMD.com

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?